It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study was designed to assess 3D vs. 1D and 2D quantitative tumor analysis for prediction of overall survival (OS) in patients with Intrahepatic Cholangiocarcinoma (ICC) who underwent conventional transarterial chemoembolization (cTACE). 73 ICC patients who underwent cTACE were included in this retrospective analysis between Oct 2001 and Feb 2015. The overall and enhancing tumor diameters and the maximum cross-sectional and enhancing tumor areas were measured on baseline images. 3D quantitative tumor analysis was used to assess total tumor volume (TTV), enhancing tumor volume (ETV), and enhancing tumor burden (ETB) (ratio between ETV and liver volume). Patients were divided into low (LTB) and high tumor burden (HTB) groups. There was a significant separation between survival curves of the LTB and HTB groups using enhancing tumor diameter (p = 0.003), enhancing tumor area (p = 0.03), TTV (p = 0.03), and ETV (p = 0.01). Multivariate analysis showed a hazard ratio of 0.46 (95%CI: 0.27–0.78, p = 0.004) for enhancing tumor diameter, 0.56 (95% CI 0.33–0.96, p = 0.04) for enhancing tumor area, 0.58 (95%CI: 0.34–0.98, p = 0.04) for TTV, and 0.52 (95%CI: 0.30–0.91, p = 0.02) for ETV. TTV and ETV, as well as the largest enhancing tumor diameter and maximum enhancing tumor area, reliably predict the OS of patients with ICC after cTACE and could identify ICC patients who are most likely to benefit from cTACE.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Charité Universitätsmedizin, Department of Diagnostic and Interventional Radiology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
2 Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
3 University of Toronto, Division of Biostatistics, Dalla Lana School of Public Health, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
4 Johns Hopkins University School of Medicine, Division of Vascular and Interventional Radiology, Russel H. Morgan Department of Radiology and Radiological Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
5 Charité Universitätsmedizin, Department of Diagnostic and Interventional Radiology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
6 Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Johns Hopkins University School of Medicine, Division of Vascular and Interventional Radiology, Russel H. Morgan Department of Radiology and Radiological Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Emory University School of Medicine, Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)